CN108853468A - A kind of compound preparation and preparation method thereof assisting in the treatment of psoriasis - Google Patents
A kind of compound preparation and preparation method thereof assisting in the treatment of psoriasis Download PDFInfo
- Publication number
- CN108853468A CN108853468A CN201810911640.6A CN201810911640A CN108853468A CN 108853468 A CN108853468 A CN 108853468A CN 201810911640 A CN201810911640 A CN 201810911640A CN 108853468 A CN108853468 A CN 108853468A
- Authority
- CN
- China
- Prior art keywords
- parts
- psoriasis
- treatment
- composition
- assisting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of compound preparations for assisting in the treatment of psoriasis, including：Assist in the treatment of 3.919-7.488 parts of psoriasis composition, 1.0-1.5 parts of suspension thickener, 7-10 parts of moisturizer, 8-10 parts of emollient, 0.5-2.5 parts of antioxidant and water；Assisting in the treatment of psoriasis composition includes：The improvement skin microcirculation composition being made of arasaponin, butcher's broom root extract and Ba 2672；The correction Keratoderma composition being made of sulfonation shale oil and Lens culinaris seed extract；The reparation damaged skin barrier compositions being made of prinsepia utilis royle oil, panthenol and hydrolyzed yeast albumen；The anti-inflammatory anti-irritant composition being made of Gotu Kola P.E, pot marigold flower extract and ammonium glycyrrhetate.The invention also discloses a kind of preparation methods of compound preparation for assisting in the treatment of psoriasis.
Description
Technical field
The present invention relates to the compound preparations and its preparation of medicine and a kind of adjuvant treatment psoriasis in personal care articles field
Method.
Background technique
Psoriasis is commonly called as psoriasis, is a kind of common chronic inflammatory skin.Its origin cause of formation is not yet clear, common trouble
Person's clinical manifestation is erythema, papule, patch and scales of skin that peel off etc., has seriously affected the appearance of psoriatic, makes its palpitation, fears
Fear, nervous irritated, depression, has seriously affected the social interaction of patient.
Studies have shown that the skin barrier function of Patients with Psoriasis is impaired, it is mainly shown as lipid between epidermal cell
Dyssynthesis, percutaneous water loss increases, dry skin, while skin epidermal cells proliferation and dyskeratosis.Common controls
The method for treating psoriasis includes external medication, the treatment of innerlich anwenden object, physiotherapy, Chinese medicine treatment and psychotherapy etc..Its
In, be applied with class therapeutic modality in moisturizing class ointment, main treatment principle be can cutin-softening layer, promotion furfur, to skin
Moistened, moisturizing, protection and repair skin barrier the effects of, belong to the basic drug of psoriasis external curing.Common
Such as urea frost, silicon frost, vitamin E cream, vaseline or glycerol.Such ointment relative components are relatively simple, and effect compares
It is more basic.In addition to this, the Common drugs for treating psoriasis further include：Glucocorticoid medicine, vitamin D 3-derivatives, dimension
A acids, Dithranol, tar class, keratoplastics, keatolytics etc., the above drug need to arrange in pairs or groups use, to mitigate respective pair
Effect.The domestic skin care item temporarily developed without the pathogenesis based on psoriasis at present, to help psoriatic safe and effective
Carry out treat.Therefore, design it is a starts with from many aspects, for a variety of mechanism, while safe and non-stimulating external application cream, be
Where needing to inquire into and solve the problems, such as now.
Summary of the invention
The purpose of the invention is to overcome the deficiencies of the prior art and provide a kind of compound preparation for assisting in the treatment of psoriasis
And preparation method, effective adjuvant treatment psoriasis, and safety are cooperateed with, it is without side-effects.
Realizing a kind of technical solution of above-mentioned purpose is：A kind of compound preparation assisting in the treatment of psoriasis, according to parts by weight
Number includes：
Assist in the treatment of 3.919-7.488 parts of psoriasis composition, 1.0-1.5 parts of suspension thickener, 7-10 parts of moisturizer, profit
8-10 parts of skin agent, 0.5-2.5 parts of antioxidant and water；
Wherein, adjuvant treatment psoriasis composition includes：
The improvement skin microcirculation composition being made of arasaponin, butcher's broom root extract and Ba 2672；
The correction Keratoderma composition being made of sulfonation shale oil and Lens culinaris seed extract；
The reparation damaged skin barrier compositions being made of prinsepia utilis royle oil, panthenol and hydrolyzed yeast albumen；
The anti-inflammatory anti-irritant composition being made of Gotu Kola P.E, pot marigold flower extract and ammonium glycyrrhetate.
Further, psoriasis composition is assisted in the treatment of, includes according to parts by weight：2.4-4.5 parts of Lens culinaris seed extract,
0.8-1.5 parts of sulfonation shale oil, 0.5-1.0 parts of panthenol, 0.1-0.2 parts of prinsepia utilis royle oil, 0.03-0.06 parts of Ba 2672, vacation
0.015-0.030 parts of leaf tree root extract, 0.01-0.02 parts of ammonium glycyrrhetate, 0.0065-0.013 parts of Gotu Kola P.E, hydrolysis
0.004-0.008 parts of Yeast protein, 0.0035-0.007 parts of pot marigold flower extract, 0.05-0.15 parts of arasaponin.
Further, the weight ratio of Lens culinaris seed extract and sulfonation shale oil is 3：1, sulfonation shale oil is shale oil
Sodium sulfonate.
Further, suspension thickener be carbomer, ammonium acryloyl taurate/VP copolymer, acrylate/
In C10-30 alkyl acrylate cross-linked copolymer, xanthan gum, the composition of any two kinds of components or any three kinds of components.
Further, moisturizer is glycerol, 1,3-BDO, 1,2-PD, 1,2- pentanediol, diglycerol, hyalomitome
Sour sodium, polyglutamic acid sodium, in glycerin polyether -26 any three kinds of components or three kinds or more component composition.
Further, emollient is Butyrospermum parkii fruit rouge, caprylic/capric triglyceride, hydrogenated coco glycerolipid, spiny dogfish
The composition of any three kinds of components or three kinds or more component in the smooth caprylate of alkane, jojoba oil, dimethyl silicone polymer, sorb.
Further, antioxidant is the combination of tocopherol, tocopherol acetate or tocopherol and tocopherol acetate
Object.
Further, also contain chelating agent in the compound preparation, and make the pH stable of the compound preparation 5.8~
6.5 neutralizer.
Realizing another technical solution of above-mentioned technical purpose is：A kind of system for the compound preparation assisting in the treatment of psoriasis
Preparation Method includes the following steps：
Water phase preparation step：Deionized water, suspension thickener, moisturizer, chelating agent are added in water phase pot, heating is stirred
It mixes, is uniformly mixed suspension thickener, moisturizer, chelating agent in deionized water, obtain water phase material, and protect water phase material
Hold 75-80 DEG C；
Oily phase preparation step：Emollient, prinsepia utilis royle oil, antioxidant are added to oily phase pot, heating and opening stirring makes
Oil phase material is obtained after emollient, prinsepia utilis royle oil and antioxidant are molten altogether, and oil phase material is made to be kept for 75-80 DEG C；
Emulsifying step：Emulsification pot temperature is risen to 75-80 DEG C and is vacuumized, using negative pressure first by the water of 2/3rds volumes
Phase materials are pumped into emulsion pot and are stirred, and then recycle negative pressure that oil phase material is pumped into emulsion pot, finally will be remaining
Water phase material is pumped into emulsion pot, and homogeneous 10min is kept the temperature at 75-80 DEG C；
Preliminary cooling step：Panthenol is added when being cooled to 55~65 DEG C；
Discharge step：After being cooled to 40~50 DEG C, Lens culinaris seed extract, sulfonation shale oil, Ba 2672, phyllodium is added
Tree root extract, Gotu Kola P.E, hydrolyzed yeast albumen, pot marigold flower extract, ammonium glycyrrhetate, arasaponin and neutralization
The pH value of product is controlled and is discharged between 5.8-6.5 by agent.
Using a kind of compound preparation of adjuvant treatment psoriasis of the invention, include according to parts by weight：Adjuvant treatment
3.919-7.488 parts of psoriasis composition, 1.0-1.5 parts of suspension thickener, 7-10 parts of moisturizer, 8-10 parts of emollient, antioxygen
0.5-2.5 parts of agent and water；Wherein, adjuvant treatment psoriasis composition includes：By arasaponin, butcher's broom root extract and
The improvement skin microcirculation composition of Ba 2672 composition；The correction skin being made of sulfonation shale oil and Lens culinaris seed extract
Skin angling composition；The reparation damaged skin barrier compositions being made of prinsepia utilis royle oil, panthenol and hydrolyzed yeast albumen；By accumulating
Avenge the anti-inflammatory anti-irritant composition of careless extract, pot marigold flower extract and ammonium glycyrrhetate composition.Its technical effect is that：Pass through
Cutin-softening corrects abnormal skin keratinization, reinforcing capillary, improves microcirculation, repairs skin barrier function, inflammation-resisting itch-stopping
Multiple pathways the compatibility of science has been carried out to active matter, be aided with moisturizing ingredient, cooperate with effective adjuvant treatment psoriasis,
And safety, it is without side-effects.
Using a kind of technical solution of the preparation method of the compound preparation of adjuvant treatment psoriasis of the invention, including with
Lower step：Water phase preparation step：Deionized water, suspension thickener, moisturizer, chelating agent are added in water phase pot, heating stirring,
It is uniformly mixed suspension thickener, moisturizer, chelating agent in deionized water, obtains water phase material, and keep water phase material
75-80℃；Oily phase preparation step：Emollient, prinsepia utilis royle oil, antioxidant are added to oily phase pot, heating and opening stirring makes
Oil phase material is obtained after emollient, prinsepia utilis royle oil and antioxidant are molten altogether, and oil phase material is made to be kept for 75-80 DEG C；Emulsifying step：
Emulsification pot temperature is risen to 75-80 DEG C and is vacuumized, the water phase material of 2/3rds volumes is first pumped into emulsion pot using negative pressure
In be stirred, then recycle negative pressure by oil phase material be pumped into emulsion pot in, finally by remaining water phase material be pumped into emulsify
Pot keeps the temperature homogeneous 10min at 75-80 DEG C；Preliminary cooling step：Panthenol is added when being cooled to 55~65 DEG C；Discharge step：Drop
Temperature is mentioned to Lens culinaris seed extract, sulfonation shale oil, Ba 2672, butcher's broom root extract, centella after 40~50 DEG C, is added
Object, hydrolyzed yeast albumen, pot marigold flower extract, ammonium glycyrrhetate, arasaponin and neutralizer are taken, the pH value of product is controlled
It discharges between 5.8-6.5.It is also able to achieve above-mentioned technical effect.
Specific embodiment
The present inventor is in order to preferably understand technical solution of the present invention, below by specifically real
Example is applied to be described in detail：
In a kind of compound preparation of adjuvant treatment psoriasis of the invention,
According to parts by weight, moisturizer is by 3-5 parts of glycerol, 1-3 parts of 1,3-BDOs, 1-3 parts of 1,2-PDs, 3-5
Part 1,2- pentanediol, 1-3 parts of diglycerols, 0.02-0.05 parts of Sodium Hyaluronates, 0.02-0.05 parts of polyglutamic acid sodium, 1-3 parts it is sweet
The composition of any three kinds of components or three kinds or more component in oily polyethers -26, the total weight number of moisturizer are 7~10 parts.
According to parts by weight, suspension thickener is carbomer 0.4-0.6 parts, ammonium acryloyldime-thyltaurate/VP is copolymerized
0.4-0.7 parts of object, acrylate/0.2-0.3 parts of C10-30 alkyl acrylate cross-linked copolymer, 0.05-0.10 parts of xanthan gum
In the composition of any two kinds of components or any three kinds of components, the total weight number of suspension thickener is 1.0-1.5 parts.
According to parts by weight, emollient is 2-4 parts of Butyrospermum parkii fruit rouge, 2-4 parts of caprylic/capric triglyceride, hydrogenation coconut palm
Oily glycerolipid 0.5-1.0 parts, 1-2 parts of saualane, 1-2 parts of jojoba oil, 1-2 parts of dimethyl silicone polymer, the smooth octanoic acid of sorb
Composition in 0.5-1.0 parts of ester more than any three kinds or three kinds of components, the total weight number of emollient are 8.0~10.0 parts.
The parts by weight of antioxidant are 0.5~1.5 part, can be 0.5-1.0 parts of tocopherols, 0.5-2.5 parts of tocopherols
The composition of acetic acid esters or 0.5-1.0 parts of tocopherol and tocopherol acetate.
According to parts by weight, psoriasis composition is assisted in the treatment of by 2.4-4.5 parts of Lens culinaris seed extract, sulfonation shale oil 0.8-
1.5 parts, 0.5-1.0 parts of panthenol, 0.1-0.2 parts of prinsepia utilis royle oil, 0.03-0.06 parts of Ba 2672, butcher's broom root extract
0.015-0.030 parts, 0.01-0.02 parts of ammonium glycyrrhetate, 0.0065-0.013 parts of Gotu Kola P.E, hydrolyzed yeast albumen
0.004-0.008 parts, 0.0035-0.007 parts of pot marigold flower extract, 0.05-0.15 parts of arasaponin compositions, adjuvant treatment
Total parts by weight of psoriasis composition are 3.919-7.488 parts.
Remaining is water, chelating agent and neutralizer.
Assist in the treatment of psoriasis composition, suspension thickener, moisturizer, emollient, antioxidant and water, chelating agent and in
Total weight number with agent is 100 parts.
The wherein preferred shale oil sodium sulfonate of sulfonation shale oil, Lens culinaris seed extract and the weight ratio of sulfonation shale oil are preferred
It is 3：1.
A kind of preparation method of the compound preparation of adjuvant treatment psoriasis of the invention, includes the following steps：
Water phase preparation step：Deionized water, suspension thickener, moisturizer, chelating agent are added in water phase pot, heating is stirred
It mixes, is uniformly mixed suspension thickener, moisturizer, chelating agent in deionized water, obtain water phase material, and protect water phase material
Hold 75-80 DEG C；
Oily phase preparation step：Emollient, prinsepia utilis royle oil, antioxidant are added to oily phase pot, heating and opening stirring makes
Oil phase material is obtained after emollient, prinsepia utilis royle oil and antioxidant are molten altogether, and oil phase material is made to be kept for 75-80 DEG C；
Emulsifying step：Emulsification pot temperature is risen to 75-80 DEG C and is vacuumized, using negative pressure first by the water of 2/3rds volumes
Phase materials are pumped into emulsion pot and are stirred, and then recycle negative pressure that oil phase material is pumped into emulsion pot, finally will be remaining
Water phase material is pumped into emulsion pot, and homogeneous 10min is kept the temperature at 75-80 DEG C；
Preliminary cooling step：When being cooled to 55~65 DEG C, panthenol is added；Discharge step：After being cooled to 40~50 DEG C, it is added
Lens culinaris seed extract, sulfonation shale oil, Ba 2672, butcher's broom root extract, Gotu Kola P.E, hydrolyzed yeast albumen,
The pH value of product is controlled and is discharged between 5.8-6.5 by pot marigold flower extract, ammonium glycyrrhetate, arasaponin and neutralizer.
Illustrate below by specific embodiment, all raw materials used in Examples 1 to 5 are as follows：
Deionized water uses and the deionized water apparatus for preparation preparation of the model DW100 of safe company；EDETATE SODIUM is selected from
Klein company, trade name Dissolvine NA2；Glycerol is selected from P&G chemical company, trade name Moon K
Glycerin；1,3-BDO is selected from U.S. OXEA, trade name 1,3-BG；1,2- pentanediol is selected from the fragrant company of moral, commodity
It is entitled5；Sodium Hyaluronate is selected from Shandong Fu Ruida company, trade name low-numerator sodium hyaluronate (HA-
TLM20-40)；Glycerin polyether -26 is selected from LIPO company, trade name LIPONIC EG-1；It is red public that polyglutamic acid sodium is selected from taste
Department, trade name Sodium Polyglutamate (HM)；Carbomer is selected from Lubrizol company, trade name CARBOPOL
ULTREZ 30 POLYMER；Acrylate/C10-30 alkyl acrylate cross-linked copolymer is selected from Lubrizol company, commodity
Entitled PEMULEN TR-1 POLYMER；Ammonium acryloyl taurate/VP copolymer is selected from Klein company, trade name
ARISTOFLEX AVC；Xanthan gum is selected from Rhodia, trade name RHODICARE H；It is public that Butyrospermum parkii fruit rouge is selected from AAK
Department, trade name LIPEX Sheasoft；Caprylic/capric triglyceride is selected from Evonik company, trade name TEGOSOFT
CT；Saualane is selected from CarOi, Line Cosmetica company, trade name EXOLIVE；Dimethyl silicone polymer is selected from road health
Ning company, trade name PMX200-350cst；Jojoba oil is selected from LIPO company, trade name DWJ Jojoba
Colorless；The smooth caprylate of sorb is selected from Klein company, trade name Velsan SC；Prinsepia utilis royle oil selects Kunming Bei Taini
Biological Co., Ltd's production；Tocopherol acetate is selected from Royal DSM company, trade name dl-a-Tocopheryl Acetate；
Tocopherol is selected from Royal DSM company, trade name dl- α-Tocopherol；Panthenol is selected from Royal DSM company, trade name D-
Panthenol；Lens culinaris seed extract selects the production of Kunming Bei Taini biology Co., Ltd；Shale oil sodium sulfonate is selected from ICHTHYOL
Company, trade name ICHTHYOL PALE；Ba 2672, butcher's broom root extract, ammonium glycyrrhetate, Gotu Kola P.E, water
Solve Yeast protein, pot marigold flower extract composition is selected from BASF AG, trade name BIOPHYTEX LS 9832；Radix Notoginseng is total
Saponin(e selects the self-produced raw material of Kunming Beitaini Biotechnology Co., Ltd.；Aminomethyl propanol is selected from Angus Chemical, commodity
Entitled AMP-ULTRA PC 2000.
Embodiment 1：
According to parts by weight, embodiment 1 includes：
79.361 parts of deionized water；
0.05 part of chelating agent EDETATE SODIUM；
3.00 parts of glycerol, 1.00 parts of 1,3 butylene glycol, 3.00 parts of 1,2- pentanediol, 0.02 part of Sodium Hyaluronate composition be total to
7.02 part moisturizer；
0.50 part of carbomer, 0.60 part of ammonium acryloyl taurate/VP copolymer, 0.05 part of xanthan gum composition
1.15 parts of suspension thickeners；
2.00 parts of Butyrospermum parkii fruit rouge, 4.00 parts of caprylic/capric triglyceride, 1.00 parts of the smooth caprylate of sorb composition be total to
7.00 part emollient；
0.50 part of antioxidant of 0.50 part of tocopherol acetate composition；
0.50 part of panthenol, 3.00 parts of Lens culinaris seed extract, 1.00 parts of shale oil sodium sulfonate, 0.03 part of Ba 2672, vacation
0.015 part of leaf tree root extract, 0.01 part of ammonium glycyrrhetate, 0.0065 part of Gotu Kola P.E, 0.004 part of hydrolyzed yeast albumen,
0.0035 part of pot marigold flower extract, 0.05 part of arasaponin, 0.10 part of prinsepia utilis royle oil total 4.719 parts of adjuvant treatments silver bits
Sick composition；
0.20 part of aminomethyl propanol as neutralizer；
It is 100 parts total.
Embodiment 2：
According to parts by weight, embodiment 2 includes：
76.781 parts of deionized water；
0.05 part of chelating agent EDETATE SODIUM；
1.00 parts of 1,3 butylene glycol, 5.00 parts, 3.00 parts glycerin polyethers -26 of 1,2- pentanediol and 0.05 part of polyglutamic acid sodium
9.05 parts of moisturizer of composition；
0.4 part of carbomer, 0.7 part of ammonium acryloyl taurate/VP copolymer, 0.05 part of xanthan gum composition 1.15
Part suspension thickener；
4.00 parts of Butyrospermum parkii fruit rouge, 2.00 parts of caprylic/capric triglyceride, 1.00 portions of the jojoba oil emollients formed
7.00 part；
0.5 part of tocopherol, 0.5 part of antioxidant of composition；
1.00 parts of panthenol, 3.00 parts of Lens culinaris seed extract, 1.00 parts of shale oil sodium sulfonate, 0.03 part of Ba 2672, vacation
0.015 part of leaf tree root extract, 0.01 part of ammonium glycyrrhetate, 0.0065 part of Gotu Kola P.E, 0.004 part of hydrolyzed yeast albumen,
The adjuvant treatment psoriasis group of 0.0035 part of pot marigold flower extract, 0.1 part of arasaponin and 0.10 part of prinsepia utilis royle oil composition
Close 5.269 parts of object；
0.2 part of aminomethyl propanol as neutralizer；
It is 100 parts total.
Embodiment 3
According to parts by weight, embodiment 3 includes：
79.242 parts of deionized water；
0.05 part of chelating agent EDETATE SODIUM；
3.00 parts of 1,3 butylene glycol, 3.00 parts, 1.00 parts glycerin polyethers -26 of 1,2- pentanediol and 0.02 part of polyglutamic acid sodium
7.02 parts of moisturizer of composition；
Acrylate/0.20 part of C10-30 alkyl acrylate cross-linked copolymer, ammonium acryloyldime-thyltaurate/VP are total
0.90 part of suspension thickener of 0.60 part and 0.10 part of xanthan gum composition of polymers；
3.00 parts of Butyrospermum parkii fruit rouge, 2.00 parts of saualane, 1.00 parts of dimethyl silicone polymer, the smooth caprylate 1.00 of sorb
7.00 parts of emollient of part composition；
1.50 parts of antioxidant of 1.50 parts of tocopherol acetate compositions；
0.10 part of prinsepia utilis royle oil, 0.50 part of panthenol, 2.40 parts of Lens culinaris seed extract, 0.80 part of shale oil sodium sulfonate, seven leaves
Set 0.06 part of saponin(e, 0.03 part of butcher's broom root extract, 0.02 part of ammonium glycyrrhetate, 0.013 part of Gotu Kola P.E, hydrolyzed yeast
0.008 part of albumen, 0.007 part of pot marigold flower extract, 0.15 part of the arasaponin adjuvant treatment psoriasis composition formed
4.09 part；
0.20 part of aminomethyl propanol；
It is 100 parts total.
Embodiment 4
According to parts by weight, embodiment 4 includes：
75.212 parts of deionized water；
0.05 part of chelating agent EDETATE SODIUM；
3.00 parts of 1,3 butylene glycol, 3.00 parts of 1,2- pentanediol, 0.05 part of Sodium Hyaluronate, 6.05 parts of moisturizer of composition；
The suspension thickener 1.00 of 0.60 part and 0.40 part of ammonium acryloyl taurate/VP copolymer composition of carbomer
Part；
2.00 parts of Butyrospermum parkii fruit rouge, 2.00 parts of caprylic/capric triglyceride, 1.00 parts of saualane, jojoba oil 2.00
Part and 1.00 parts of the smooth caprylate of sorb 8.00 parts of emollient formed；
2.50 parts of antioxidant of 1.00 parts and 1.50 parts of tocopherol acetate compositions of tocopherol；
0.20 part of prinsepia utilis royle oil, 0.50 part of panthenol, 4.50 parts of Lens culinaris seed extract, 1.50 parts of shale oil sodium sulfonate, seven leaves
Set 0.06 part of saponin(e, 0.03 part of butcher's broom root extract, 0.02 part of ammonium glycyrrhetate, 0.013 part of Gotu Kola P.E, hydrolyzed yeast
0.008 part of albumen, 0.007 part of pot marigold flower extract, 0.15 part of the arasaponin adjuvant treatment psoriasis composition formed
6.99 part；
0.20 part of aminomethyl propanol as neutralizer；
It is 100 parts total.
Embodiment 5
According to parts by weight, embodiment 5 includes：
78.291 parts of deionized water；
0.05 part of EDETATE SODIUM
3.00 parts of glycerol, 3.00 parts of 1,2- pentanediol, 0.02 part, 1.00 parts glycerin polyethers -26 of Sodium Hyaluronate and poly- paddy
7.04 parts of moisturizer of 0.02 part of propylhomoserin sodium composition；
0.50 part of carbomer, 0.60 part of ammonium acryloyl taurate/VP copolymer, 0.05 part of xanthan gum composition it is outstanding
Floating 1.15 parts of thickener；
2.00 parts of Butyrospermum parkii fruit rouge, 2.00 parts of caprylic/capric triglyceride, 2.00 parts of saualane, jojoba oil 1.00
Part and 1.00 parts of the smooth caprylate of sorb 8 parts of emollient formed；
The antioxidant that tocopherol acetate 0.50 forms；
0.10 part of prinsepia utilis royle oil, 0.50 part of panthenol, 3.00 parts of Lens culinaris seed extract, 1.00 parts of shale oil sodium sulfonate, seven leaves
Set 0.03 part of saponin(e, 0.015 part of butcher's broom root extract, 0.01 part of ammonium glycyrrhetate, 0.0065 part of Gotu Kola P.E, hydrolysis ferment
The adjuvant treatment psoriasis group of 0.004 part of female albumen, 0.0035 part of pot marigold flower extract and 0.10 part of arasaponin composition
Close 4.689 parts of object；
0.20 part of aminomethyl propanol as neutralizer；
It is 100 parts total.
Examples 1 to 5 is tested below：
Stability test
Study on the stability test is carried out to the compound preparation of the adjuvant treatment psoriasis of the above-mentioned embodiment 1-5 prepared,
Successively under -15 DEG C, 5 DEG C, 40 DEG C, 49 DEG C and room temperature, observes 30 days, 60 days and 90 days respectively, whether determine embodiment 1-5
There are liquid phase separation situations, if observing liquid phase separation, for by stability test, after tested, Examples 1 to 5 is all logical
Overstability test.
Security test
Multiple Skin Irritation Test, acute ocular are successively carried out to the compound preparation of the adjuvant treatment psoriasis of embodiment 1-5
Irritation test, Skin allergy test and skin phototoxicity test.
Multiple Skin Irritation Test, each embodiment are carried out to the compound preparation of the adjuvant treatment psoriasis of Examples 1 to 5
4 albino guinea-pigs of test selection, test room temperature：20~24 DEG C, relative humidity：60~70%.Before test about for 24 hours, test
Preceding to cut experimental animal back backbone two sides coat, unhairing range is respectively 2 × 3cm, 2.5 × 2.5cm of application area.It takes tested
Object about 0.5mL is applied on the skin of side, and when tested material is prepared using nonirritant solvent, the other side applies Examples 1 to 5 and makees
For control, smear 1 time daily, it is continuous to smear 14 days.Since second day, cropping is answered before smearing every time, with water or nonirritant
Solvent cleaning remains tested material.Observation is as a result, reference after one hour《Cosmetics health specification (2007 editions)》Regulation is stimulated
Reaction scoring.The scoring of Examples 1 to 5, erythema and oedema on all animal skins is 0 point.Safety is reliable.
Acute eye irritation test is carried out to the compound preparation of the adjuvant treatment psoriasis of embodiment 1 to 5, each embodiment is equal
It selects 3 healthy adult white rabbits to be tested, tests room temperature：20-24 DEG C, relative humidity：60-70%.It is dynamic before test
Object will at least adapt to 3 day time in experimental animal room environment.A palpebra inferior for hairy rat side eyes is pulled open, by tested material
0.1mL (100mg) is instilled in (or being painted into) conjunctival sac, so that upper and lower eyelid is passively closed 1s, to prevent tested material from losing.It is another
Branch hole eyeball, which is not handled, makees own control.Eyes are not rinsed in 24 hours after instilling tested material.1 after instilling tested material, 24,48,
Animal eyes were checked in 72 hours and the 4th day and the 7th day.If 72 hours do not occur stimulate the reaction, examination can be terminated
It tests.If it find that involve cornea or there are other Eye irritations to act on, not recuperator in 7 days, for the invertibity or not for determining the damage
Invertibity need to extend observing time, be usually no more than 21 days.Reference《Cosmetics health specification (2007 editions)》Regulation is stimulated
Reaction scoring.Examples 1 to 5 does not find acute ocular stimulate the reaction.
Skin allergy test, that is, anaphylaxis is carried out to the compound preparation of the adjuvant treatment psoriasis of embodiment 1 to 5 to connect
Touching property dermatitis test, to determine if that skin allergic reaction and degree can be caused.Control group selects distilled water, and positive group is used
0.4% 2,4- dinitro-chloro-benzene acetone soln.Experiment plants Albino guinea pig using regular grade Britain, is divided into three groups, every group 20
Only.19-26 DEG C of experimental animal feeding temperature, relative humidity 40-70%.For 24 hours by shaving on the left of guinea pig back before test, area is about
6c㎡.Induction exposure：The tested material 0.2g of induction is coated in the region shaving 2cm × 2cm on the left of tested material test group of animals
On skin, with two layers of gauze, one layer of glassine paper covering, 6h is closed in immobilization with adhesive tape.It repeats in the same way within 7th day and 14 days
Once.The positive organizes 2, the 4- dinitro-chloro-benzene acetone soln with 0.4%, and tested material control group makes together of 0.2ml physiological saline
Sample processing.Excitation contact；14 days after last induction, excitation is coated in tested material experimental group with tested material and control animals are right
Side is on the skin in the preceding region shaving 2cm × 2cm for 24 hours, and with two layers of gauze, one layer of glassine paper covering, 6h is closed in immobilization with adhesive tape.
Positive group does same excitation contact with 0.4% 2,4- dinitro-chloro-benzene acetone soln.In for 24 hours, 48h observe dermoreaction,
Reference《Cosmetics health specification (2007 editions)》Regulation carries out dermoreaction scoring and sensitization strength grading.The institute of Examples 1 to 5
Having evaluation result is 0 point, will not cause contact skin allergic reaction.
Skin phototoxicity test is carried out to the compound preparation of the adjuvant treatment psoriasis of embodiment 1 to 5, it is determined whether have
Cause phototoxic possibility.
The preceding 18h of progress light poison test~for 24 hours, by animal backbone two sides skin unhairing, experiment position skin need to be intact, lossless
Injure exception.Standby four pieces are gone to hair-fields, and it is about 2cm × 2cm that every piece, which is removed hair-fields area,.Animal is fixed, removes two pieces of unhairings in animal
Area coats tested material, and two pieces are gone to hair-fields not apply tested material, two pieces of coating tested materials go to hair-fields and two pieces do not apply tested material unhairing
Respectively there is one piece of progress UVA irradiation in area, and one piece does not receive UVA irradiation, and do not receive UVA irradiation goes to hair-fields to be covered with aluminium foil.It is used
Tested material concentration cannot cause skin wound repair, respectively in 1h, for 24 hours, 48h and 72h observe dermoreaction, according to《Cosmetics
Hygienic practice (2007 editions)》Determine every animal skin reaction scoring.Embodiment 1 to 5 is tested by phototoxicity.
Both effectiveness test
By German CK company Sebumeter SM815 skin evaluation center instrument, popped one's head in different tests, in temperature 22
± 2 DEG C, under the test condition of humidity 50 ± 10%, with moisture of skin, percutaneous water loss, i.e. TEWL two indices are evaluation mark
Standard, to embodiment 1 and control sample, i.e. 15% urea frost is tested.Test number is 11 people, and test zone is in left hand arm
Side, testing time 0min, 30min, 60min, 120min, subject uses cleansing soap on a left side under tester's guidance before testing
Hand inboard arm carries out cleaning of looping, and wash number is 5 times, blots extra moisture after rinsing well with paper handkerchief, and subject needs
Sitting quietly in test cabinet can be tested after 30min, and arm is constantly exposed in air dduring test.Test result
As shown in table 1：
1 embodiment 1 of table and 15% urea frost treatment psoriasis effect compare
Test result is shown：During slight damage and test due to having carried out skin barrier to recipient site before the test
Recipient site is constantly exposed in air, and the test initial value of subject TEWL is made to be apparently higher than the TEWL value of normal skin, because
The passage of the percutaneous water loss amount of this blank group at any time persistently rises, and control group and embodiment 1 are after smearing end 30min
Impaired skin barrier can be repaired in time, and the improvement of embodiment 1 amplitude is bigger, over time, the effect of control group
It gradually decreases, and steadily even tool raising trend, embodiment 1 repair skin barrier to the skin barrier repairing effect of embodiment 1
Multiple effect is substantially better than control group.
1 moisture content of skin of embodiment is apparently higher than blank group and control group.
Therefore, the compound preparation of adjuvant treatment psoriasis of the invention skin barrier reparation, moisturizing and persistently moisten energy
Power test result is superior to 15% urea cream commonly used in the prior art.The percutaneous moisture stream of psoriatic can be improved well
It loses and increases, the symptom of dry skin assists in the treatment of psoriasis, reduces the use of hormone medicine, and more safety is mild.
Those of ordinary skill in the art it should be appreciated that more than embodiment be intended merely to illustrate the present invention,
And be not used as limitation of the invention, as long as to the variations of above embodiments, becoming in spirit of the invention
Type will all be fallen within the scope of claims of the present invention.
Claims (9)
1. a kind of compound preparation for assisting in the treatment of psoriasis, which is characterized in that include according to parts by weight：
Assist in the treatment of 3.919-7.488 parts of psoriasis composition, 1.0-1.5 parts of suspension thickener, 7-10 parts of moisturizer, emollient
8-10 parts, 0.5-2.5 parts of antioxidant and water；
Wherein, adjuvant treatment psoriasis composition includes：
The improvement skin microcirculation composition being made of arasaponin, butcher's broom root extract and Ba 2672；
The correction Keratoderma composition being made of sulfonation shale oil and Lens culinaris seed extract；
The reparation damaged skin barrier compositions being made of prinsepia utilis royle oil, panthenol and hydrolyzed yeast albumen；
The anti-inflammatory anti-irritant composition being made of Gotu Kola P.E, pot marigold flower extract and ammonium glycyrrhetate.
2. a kind of compound preparation for assisting in the treatment of psoriasis according to claim 1, it is characterised in that：Assist in the treatment of psoriasis group
Object is closed, includes according to parts by weight：2.4-4.5 parts of Lens culinaris seed extract, 0.8-1.5 parts of sulfonation shale oil, panthenol 0.5-1.0
Part, 0.1-0.2 parts of prinsepia utilis royle oil, 0.03-0.06 parts of Ba 2672,0.015-0.030 parts of butcher's broom root extract, glycyrrhizic acid
0.01-0.02 parts of ammonium, 0.0065-0.013 parts of Gotu Kola P.E, 0.004-0.008 parts of hydrolyzed yeast albumen, pot marigold mention
Take 0.0035-0.007 parts of object, 0.05-0.15 parts of arasaponin.
3. a kind of compound preparation for assisting in the treatment of psoriasis according to claim 2, it is characterised in that：Lens culinaris seed extract and sulphur
The weight ratio for changing shale oil is 3：1, sulfonation shale oil is shale oil sodium sulfonate.
4. a kind of compound preparation for assisting in the treatment of psoriasis according to claim 1, it is characterised in that：Suspension thickener is card wave
Nurse, ammonium acryloyl taurate/VP copolymer, acrylate/C10-30 alkyl acrylate cross-linked copolymer, xanthan gum
In, the composition of any two kinds of components or any three kinds of components.
5. a kind of compound preparation for assisting in the treatment of psoriasis according to claim 1, it is characterised in that：Moisturizer be glycerol, 1,
It is 3- butanediol, 1,2- propylene glycol, 1,2- pentanediol, diglycerol, Sodium Hyaluronate, polyglutamic acid sodium, any in glycerin polyether -26
The composition of three kinds of components or three kinds or more component.
6. a kind of compound preparation for assisting in the treatment of psoriasis according to claim 1, it is characterised in that：Emollient is Butyrospermum parkii
Fruit rouge, caprylic/capric triglyceride, hydrogenated coco glycerolipid, saualane, jojoba oil, dimethyl silicone polymer, sorb are smooth
The composition of any three kinds of components or three kinds or more component in caprylate.
7. a kind of compound preparation for assisting in the treatment of psoriasis according to claim 1, it is characterised in that：Antioxidant is fertility
The composition of phenol, tocopherol acetate or tocopherol and tocopherol acetate.
8. a kind of compound preparation for assisting in the treatment of psoriasis according to claim 1, it is characterised in that：Also contain in the compound preparation
There is chelating agent, and makes neutralizer of the pH stable of the compound preparation 5.8~6.5.
9. a kind of preparation method for the compound preparation for assisting in the treatment of psoriasis, includes the following steps：
Water phase preparation step：Deionized water, suspension thickener, moisturizer, chelating agent are added in water phase pot, heating stirring makes
Suspension thickener, moisturizer, chelating agent are uniformly mixed in deionized water, obtain water phase material, and water phase material is made to keep 75-
80℃；
Oily phase preparation step：Emollient, prinsepia utilis royle oil, antioxidant are added to oily phase pot, heating and opening stirring makes moisturizing
Oil phase material is obtained after agent, prinsepia utilis royle oil and antioxidant are molten altogether, and oil phase material is made to be kept for 75-80 DEG C；
Emulsifying step：Emulsification pot temperature is risen to 75-80 DEG C and is vacuumized, using negative pressure first by the aqueous-phase material of 2/3rds volumes
Material is pumped into emulsion pot and is stirred, and then recycles negative pressure that oil phase material is pumped into emulsion pot, finally by remaining water phase
Material is pumped into emulsion pot, and homogeneous 10min is kept the temperature at 75-80 DEG C；
Preliminary cooling step：Panthenol is added when being cooled to 55~65 DEG C；
Discharge step：After being cooled to 40~50 DEG C, Lens culinaris seed extract, sulfonation shale oil, Ba 2672, phyllodium tree root is added
Extract, Gotu Kola P.E, hydrolyzed yeast albumen, pot marigold flower extract, ammonium glycyrrhetate, arasaponin and neutralizer,
The pH value of product is controlled and is discharged between 5.8-6.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810911640.6A CN108853468B (en) | 2018-08-10 | 2018-08-10 | Compound preparation for adjuvant therapy of psoriasis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810911640.6A CN108853468B (en) | 2018-08-10 | 2018-08-10 | Compound preparation for adjuvant therapy of psoriasis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108853468A true CN108853468A (en) | 2018-11-23 |
| CN108853468B CN108853468B (en) | 2022-04-26 |
Family
ID=64318459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810911640.6A Active CN108853468B (en) | 2018-08-10 | 2018-08-10 | Compound preparation for adjuvant therapy of psoriasis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108853468B (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002265324A (en) * | 2001-03-07 | 2002-09-18 | Ichimaru Pharcos Co Ltd | Cosmetic composition containing moisture retention plant extract |
| CN102764217A (en) * | 2012-07-29 | 2012-11-07 | 何黎 | Functional skin care product containing purslane extractive and preparation method thereof |
| CN105007895A (en) * | 2013-11-22 | 2015-10-28 | 玫琳凯有限公司 | Compositions for sensitive skin |
| CN105560128A (en) * | 2016-03-01 | 2016-05-11 | 广东轻工职业技术学院 | Composition with efficacy of inhibiting sebum secretion and use of composition |
| CN105796620A (en) * | 2016-02-23 | 2016-07-27 | 广西梧州制药（集团）股份有限公司 | New applications of radix notoginseng and radix notoginseng extract to preparation of medicines for treating psoriasis |
| US9642887B1 (en) * | 2015-12-28 | 2017-05-09 | Shetal Amit Shah | Anti-blepharitis compositions and their use |
| CN106727149A (en) * | 2017-01-04 | 2017-05-31 | 广州聚澜健康产业研究院有限公司 | A kind of gentle makeup remover of compacting |
| CN107629104A (en) * | 2017-09-18 | 2018-01-26 | 昆明贝泰妮生物科技有限公司 | Triterpenoid saponin medical compounds and its preparation and application |
-
2018
- 2018-08-10 CN CN201810911640.6A patent/CN108853468B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002265324A (en) * | 2001-03-07 | 2002-09-18 | Ichimaru Pharcos Co Ltd | Cosmetic composition containing moisture retention plant extract |
| CN102764217A (en) * | 2012-07-29 | 2012-11-07 | 何黎 | Functional skin care product containing purslane extractive and preparation method thereof |
| CN105007895A (en) * | 2013-11-22 | 2015-10-28 | 玫琳凯有限公司 | Compositions for sensitive skin |
| US9642887B1 (en) * | 2015-12-28 | 2017-05-09 | Shetal Amit Shah | Anti-blepharitis compositions and their use |
| CN105796620A (en) * | 2016-02-23 | 2016-07-27 | 广西梧州制药（集团）股份有限公司 | New applications of radix notoginseng and radix notoginseng extract to preparation of medicines for treating psoriasis |
| CN105560128A (en) * | 2016-03-01 | 2016-05-11 | 广东轻工职业技术学院 | Composition with efficacy of inhibiting sebum secretion and use of composition |
| CN106727149A (en) * | 2017-01-04 | 2017-05-31 | 广州聚澜健康产业研究院有限公司 | A kind of gentle makeup remover of compacting |
| CN107629104A (en) * | 2017-09-18 | 2018-01-26 | 昆明贝泰妮生物科技有限公司 | Triterpenoid saponin medical compounds and its preparation and application |
Non-Patent Citations (6)
| Title |
|---|
| STEFAN BECKERT MD，等: "Efficacy of topical pale sulfonated shale oil in the treatment of venous leg ulcers: A randomized, controlled, multicenter study", 《JOURNAL OF VASCULAR SURGERY》 * |
| 佚名: "薇诺娜舒敏保湿修红霜", 《网址：HTTP://WWW.AIQILIAN.COM/PID/I7VAG0PD.HTML》 * |
| 巴斯夫: "Biophytex LS 9832", 《网页证据：HTTP://WWW.BAIWANX.CN/USERLIST/HKMY/NEWSHOW-45293.HTML》 * |
| 张卫明，等: "《一带一路经济植物》", 30 November 2007, 东南大学出版社 * |
| 张蕾，等: "青刺果油的保湿性研究", 《日用化学品科学》 * |
| 林蕾，等: "《美容皮肤治疗技术》", 31 January 2017, 华中科技大学出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108853468B (en) | 2022-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109091411A (en) | A kind of infant's lotion and preparation method thereof | |
| MXPA04000002A (en) | Agent containing fat (oil), which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue. | |
| CN106361599A (en) | Multi-vegetable-oil-containing infantile eczema care cream | |
| CN111700853B (en) | Cosmetic composition with anti-allergy repairing effect and application thereof | |
| CN109431873B (en) | Composition for repairing and relieving skin inflammation | |
| US11090205B2 (en) | Methods and compositions for treatment of skin conditions | |
| WO2018049608A1 (en) | Quantum light wave erugation and skincare cream and preparation method therefor | |
| CN107982180A (en) | A kind of anti-inflammatory antiallergic mask and preparation method thereof | |
| US10496949B2 (en) | Compositions and methods for treating cutaneous conditions | |
| CN110859762B (en) | Gel containing Camellia japonica extract and having after-sun repair effect and preparation method thereof | |
| CN111419773B (en) | Plant extract composition for skin aging resistance and repair, application thereof and essence containing composition | |
| CN111481475A (en) | Edible lipstick capable of improving female hormone and preparation method thereof | |
| US8557795B2 (en) | Composition containing Chamaecyparis obtusa polysaccharides to be externally applied to the skin | |
| CN111083923A (en) | Soothing cream and preparation method thereof | |
| US6193975B1 (en) | Use of potentilla erecta extract in the cosmetic and pharmaceutical field | |
| CN113456568A (en) | Composition for soothing, repairing and moisturizing skin and preparation method and application thereof | |
| CN113332160A (en) | Cosmetic composition for conditioning peritrichotic skin | |
| CN112472648A (en) | Soothing cream containing CBD cannabidiol and preparation method thereof | |
| CN108853468A (en) | A kind of compound preparation and preparation method thereof assisting in the treatment of psoriasis | |
| KR20160036834A (en) | Skin external application composition comprising complex fermented extract of crude drug ingredients | |
| CN112057388A (en) | Cream for striae gravidarum repair and preparation method thereof | |
| RU2681850C1 (en) | Means stimulating reparation of tissues with thermal burns | |
| US10786441B2 (en) | Skin barrier repair and maintenance composition | |
| JP2005015375A (en) | External preparation for skin, characterized by containing exocrine polysaccharide obtained from alteromonas macleodii | |
| KR20150105550A (en) | Cosmetic composition comprising mucus extract from spawn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 650106 No. 53, Ke Yan Road, hi tech Zone, Kunming, Yunnan. Applicant after: Yunnan Beitani Biotechnology Group Co., Ltd. Applicant after: SHANGHAI BEITAINI BIOTECHNOLOGY CO., LTD. Address before: 650000 Kunming hi tech Zone, Yunnan Province, Department of medicine No. 53 Applicant before: KUNMING BOTANEE BIOLOGICAL TECHNOLOGY Co.,Ltd. Applicant before: SHANGHAI BEITAINI BIOTECHNOLOGY CO., LTD. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |